2495742-34-0
Chemical Structure
AZ14170133
Synonym(s): SG 3932; AZ-0133
- CAS No.: 2495742-34-0
- Formula:C57H77N7O18
- Molecular Weight:1148.26
IUPAC Name: 1-methyl-6,6-bis(methyl-d3)-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
InChIKey: OYYHJMUXFQIRBT-ZHSICCDKSA-N
SMILES: O=C1N2C(C(C(C2)=C3C4=C5CCC3)=NC4=CC=C5NC([C@H](C)NC([C@H](C(C)C)NC(CCOCCOCCOCCOCCOCCOCCOCCOCCNC(CCN6C(C=CC6=O)=O)=O)=O)=O)=O)=CC7=C1COC([C@]7(O)CC)=O
Biological Activity: AZ14170133 (SG 3932; AZ-0133) is a Drug-Linker Conjugates for ADC. AZ14170133 consists of the ADC cytotoxic payload topoisomerase 1 inhibitor and a linker. AZ14170133 can be used for synthesis of ADC AZD9592 (HY-171124) and AZD 8205 (HY-171689). AZ14170133 can be used for the research of cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZ14170133 | 99.73% | AZ14170133 (SG 3932; AZ-0133) is a Drug-Linker Conjugates for ADC. AZ14170133 consists of the ADC cytotoxic payload topoisomerase 1 inhibitor and a linker. AZ14170133 can be used for synthesis of ADC AZD9592 (HY-171124) and AZD 8205 (HY-171689). AZ14170133 can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AZ14170133-d5 | AZ14170133-d5 (SG 3932-d5) is the deuterium labeled AZ14170133 (HY-145399). AZ14170133 (SG 3932) is a Drug-Linker Conjugates for ADC, which comprises a topoisomerase inhibitor and a linker for ligand unit connecting. AZ14170133 can be used to synthesis antibody-drug conjugate (ADC). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. McGrath L, et al. Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate[J]. Cancer Research, 2023, 83(7_Supplement): 5737-5737.
- [2]. Kinneer K, et al. Design and preclinical evaluation of a novel B7-H4–directed antibody–drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305[J]. Clinical Cancer Research, 2023, 29(6): 1086-1101. [Content Brief]
Keywords
